Editorial note: this article summarises published research on retatrutide. Baclabs does not sell retatrutide or any peptide; we supply bacteriostatic water and reconstitution consumables. Nothing here is medical advice.
Retatrutide (LY3437943) is an investigational once-weekly peptide from Eli Lilly that activates three receptors at once: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. Its phase 2 trial, published in the New England Journal of Medicine in 2023, reported 24.2% mean weight loss at 48 weeks at the highest dose [1]. The phase 3 TRIUMPH programme, reporting through 2025 and 2026, has pushed that to 28.3% at 80 weeks and 30.3% at 104 weeks [2].
Those numbers exceed anything seen with semaglutide or tirzepatide, which is why retatrutide attracts so much attention and so much grey-market selling. This article explains the triple-agonist mechanism, sets out the retatrutide clinical trials in detail, reviews the adverse-effect signals, and addresses the “retatrutide buy online” question directly: as of September 2026 the compound is not licensed anywhere, and nothing sold under its name is a legitimate medicine. It sits under the GLP-1 peptides guide.
How a triple agonist works
The two incretin receptors are familiar from earlier drugs. GLP-1 receptor activation increases glucose-dependent insulin secretion, slows gastric emptying and suppresses appetite through the hypothalamus and brainstem. GIP receptor activation adds insulin secretion and, in tirzepatide’s case, appears to improve insulin sensitivity and blunt nausea. The tirzepatide vs semaglutide article covers that dual pathway.
Glucagon is the unusual third target. Glucagon normally opposes insulin, driving the liver to release glucose. On its own it would be a poor obesity drug. But glucagon receptor activation also raises energy expenditure, increases hepatic fat oxidation and reduces liver fat. The design premise of retatrutide is that the GLP-1 and GIP components restrain glucagon’s hyperglycaemic effect while the glucagon component adds a calorie-burning mechanism the incretins alone lack. The phase 3 TRIUMPH-2 trial in people with type 2 diabetes later reported HbA1c reductions of up to 1.6 percentage points, which supports that premise [4].
Retatrutide is a single peptide with a fatty acid chain for albumin binding, which is what allows weekly dosing, and modifications that confer activity at all three receptors.
Retatrutide clinical trials: phase 2
The phase 2 obesity trial (NCT04881760) randomised 338 adults with a BMI of 30 or above, or 27 with a weight-related condition, and without diabetes, to placebo or retatrutide 1, 4, 8 or 12 mg weekly for 48 weeks. Some arms began at 2 mg and escalated to reduce gastrointestinal effects. Results, as least-squares mean change from baseline, were [1][3]:
| Arm | Weight change at 24 weeks | Weight change at 48 weeks |
|---|---|---|
| Placebo | −1.6% | −2.1% |
| Retatrutide 1 mg | −7.2% | −8.7% |
| Retatrutide 4 mg | −12.9% | −17.1% |
| Retatrutide 8 mg | −17.3% | −22.8% |
| Retatrutide 12 mg | −17.5% | −24.2% |
Adverse events leading to discontinuation occurred in 6–16% of retatrutide recipients and in none of the placebo group, and heart rate rose in a dose-dependent way through week 24 before declining [3]. Doses in this section are those studied in the trial, not recommendations.
The TRIUMPH phase 3 programme
Lilly’s phase 3 programme reported topline results across four trials between December 2025 and July 2026. The figures below are from company announcements; full peer-reviewed publications were not available at the time of writing.
| Trial | Population | N | Duration | Mean weight change (retatrutide vs placebo) |
|---|---|---|---|---|
| TRIUMPH-1 [2] | Obesity, no diabetes | 2,339 | 80 weeks | −19.0% (4 mg), −25.9% (9 mg), −28.3% (12 mg) vs −2.2% |
| TRIUMPH-2 [4] | Type 2 diabetes with obesity | 1,152 | 80 weeks | −12.7% (4 mg), −19.1% (9 mg), −20.8% (12 mg) vs −4.0% |
| TRIUMPH-3 [4] | Severe obesity with cardiovascular disease | 1,949 | 80 weeks | −21.6% (9 mg), −22.6% (12 mg) vs −3.2% |
| TRIUMPH-4 [5] | Obesity with knee osteoarthritis | 445 | 68 weeks | −26.4% (9 mg), −28.7% (12 mg) vs −2.1% |
In TRIUMPH-1, a 532-participant extension to 104 weeks in people with a BMI of 35 or above reached −30.3% on 12 mg [2]. TRIUMPH-2 reported HbA1c reductions of up to 1.6 percentage points from a baseline of 7.7% [4]. TRIUMPH-4 paired weight loss with a 4.4–4.5 point reduction in WOMAC knee pain score versus 2.4 with placebo [5].
Lilly plans to submit a Biologics License Application to the US Food and Drug Administration in the first quarter of 2027 [4]. No UK or EU timeline has been announced.
Adverse effects and open questions
Retatrutide’s tolerability profile is recognisably that of the incretin class, but heavier. In TRIUMPH-1, nausea affected 28.6–42.4% of participants, diarrhoea 25.2–34.1% and constipation 23.8–26.1%. Discontinuation for adverse events rose with dose, from 4.1% at 4 mg to 11.3% at 12 mg, against 4.9% on placebo [2]. In TRIUMPH-4, the equivalent figures were 12.2% and 18.2% for 9 and 12 mg versus 4.0% [5].
Two signals are more specific to retatrutide. Dysesthesia, an abnormal skin sensation such as tingling or altered sensitivity, was reported by 8.8% of participants at 9 mg and 20.9% at 12 mg in TRIUMPH-4, against 0.7% on placebo [5]. And the phase 2 heart-rate rise, dose-dependent through week 24 before declining, remains under evaluation; whether it is a glucagon-receptor effect is not established [3].
Class warnings will almost certainly carry over: the UK Medicines and Healthcare products Regulatory Agency (MHRA) strengthened pancreatitis warnings for all GLP-1 and GIP/GLP-1 agonists in January 2026 [6], and the US semaglutide label carries a boxed warning based on rodent thyroid C-cell tumours [7]. No retatrutide outcomes trial has reported.
Retatrutide buy online: what is actually being sold
Retatrutide holds no marketing authorisation in the UK, the EU, the US or anywhere else. Any product presented for treating obesity falls under the Human Medicines Regulations 2012, but no licensed retatrutide product exists for a prescriber to prescribe. Every website offering it is therefore either selling an unlicensed medicine to the public, which is an offence, or selling a “research chemical” labelled as not for human use.
The MHRA has treated this market as an enforcement target. In October 2025 it dismantled a facility in the East Midlands producing counterfeit tirzepatide pens and unlicensed retatrutide pens [8]. In May 2026 it made two arrests during what it called its largest ever seizure of unlicensed weight-loss medicines, roughly 12,000 doses, with retatrutide named among the products [9]. The agency’s head of criminal enforcement summarised the position: “Medicines regulation isn’t discretionary; it exists to protect people.”
Evaluating a research-grade vial
For laboratories with a legitimate research use, the same questions apply as to any grey-market peptide. A certificate of analysis (CoA) should come from a named third-party laboratory, not the vendor, and show high-performance liquid chromatography (HPLC) purity, mass spectrometry confirming the expected molecular mass, and ideally endotoxin testing. A purity figure without a chromatogram, or a CoA that cannot be matched to the batch number on the vial, is not evidence. Even a genuine CoA describes the batch as tested, not the vial in hand. The research peptide purity and regulation article covers CoA reading in depth.
Reconstitution notes
Grey-market retatrutide vials are lyophilised powder, typically labelled 10–20 mg. The arithmetic is the same as for any peptide: concentration in mg/mL equals vial mass divided by diluent volume. A 10 mg vial with 2 mL of bacteriostatic water gives 5 mg/mL (5,000 mcg/mL), so each unit on a U-100 insulin syringe holds 50 mcg. Because such a vial is drawn from repeatedly over weeks, a preserved diluent is required; see bacteriostatic vs sterile water and the 28-day storage guide. Baclabs supplies UK-stocked bacteriostatic water in 30 mL vials; the reconstitution guide has the full method, and the GLP-1 reconstitution protocols article has worked tables.
Frequently asked questions
What is retatrutide?
Retatrutide is an investigational once-weekly injectable peptide developed by Eli Lilly that activates GIP, GLP-1 and glucagon receptors. Adding glucagon receptor activity is intended to raise energy expenditure alongside the appetite suppression of the incretin pathways. It reported 24.2% weight loss at 48 weeks in phase 2 and up to 28.3% at 80 weeks in phase 3 [1][2].
Is retatrutide approved in the UK?
No. As of September 2026 retatrutide has no marketing authorisation in the UK, EU or US. Lilly has said it intends to file with the FDA in the first quarter of 2027 [4]. Until a licence is granted, it cannot be prescribed, and the MHRA has seized products sold under its name during 2025 and 2026 [8][9].
What doses were used in retatrutide clinical trials?
Phase 2 tested 1, 4, 8 and 12 mg weekly, with some arms starting at 2 mg and escalating [1]. Phase 3 TRIUMPH trials used 4, 9 and 12 mg weekly maintenance doses [2][4]. These are trial doses reported for context; no licensed dosing exists, and no self-administration guidance can be derived from them.
What are retatrutide’s side effects?
Gastrointestinal effects dominate: nausea in up to 42.4%, diarrhoea up to 34.1% and constipation up to 26.1% in TRIUMPH-1 [2]. Dysesthesia (skin tingling) reached 20.9% at 12 mg in TRIUMPH-4 [5], and phase 2 showed a dose-dependent heart-rate rise [3]. Discontinuation for adverse events reached 11.3–18.2% at the highest dose across trials.
Can you buy retatrutide online legally?
Not as a medicine. No licensed retatrutide product exists, so any sale for human use is a sale of an unlicensed medicine. Vendors marketing it as a research chemical rely on “not for human consumption” labelling, and purity is unverified unless a batch-matched third-party CoA is available. The MHRA has seized such products in 2025 and 2026 [8][9].
References
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. Jastreboff AM et al., New England Journal of Medicine, 2023. doi:10.1056/NEJMoa2301972; PubMed 37366315
- Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1, NCT05929066). Eli Lilly, May 2026
- Results of phase 2 trial with GIP, GLP-1, and glucagon receptor agonist to treat obesity. PACE-CME summary of Jastreboff et al., 2023
- Retatrutide successful in two additional Phase 3 obesity trials (TRIUMPH-2 and TRIUMPH-3). Eli Lilly, July 2026
- Retatrutide delivered weight loss of up to an average of 71.2 lbs along with relief from osteoarthritis pain (TRIUMPH-4, NCT05931367). Eli Lilly, December 2025
- GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis. MHRA Drug Safety Update, January 2026
- WEGOVY (semaglutide) injection, US Prescribing Information. FDA, 2025
- UK regulators seize illegal weight loss drugs amid global pricing shake-up. Pharmaceutical Technology, October 2025
- Two arrested during the MHRA’s largest ever seizure of unlicensed weight loss medicines. MHRA / GOV.UK, May 2026
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Bacteriostatic water is supplied for reconstitution of substances intended for research and for use as directed by a healthcare professional. Peptides and medicines discussed here may be unlicensed in the UK or prescription-only; consult a qualified clinician before using any medicine. Baclabs does not sell peptides.